Global Targeted DNA/RNA Sequencing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

This report extensively covers different segments of Global Targeted DNA/RNA Sequencing Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments.

The Global NGS Targeted DNA/RNA Sequencing Market encompasses a wide array of technologies, methods, applications, workflows, and end-users, reflecting the diverse landscape of genomic research and clinical diagnostics. Within the realm of technology, next-generation sequencing (NGS) reigns supreme, driving the market's growth with its unparalleled speed, scalability, and cost-effectiveness. Methodologies within this market segment include exome sequencing, enrichment sequencing, amplicon sequencing, and other specialized approaches, each tailored to capture specific regions of interest within the genome or transcriptome.

The market's applications span a spectrum of scientific disciplines and clinical specialties, ranging from cancer gene sequencing and inherited disease screening to drug development, forensic genomics, and microbial analysis through 16S ribosomal RNA (rRNA) sequencing. This diverse array of applications underscores the versatility of targeted DNA/RNA sequencing technologies in addressing multifaceted challenges across biomedical research, healthcare, agriculture, and beyond.

Global Targeted DNA/RNA Sequencing Segment Analysis

In this report, the Global Targeted DNA/RNA Sequencing Market has been segmented by Technology, Workflow, Application, Type, End Use and Geography.

Global Targeted DNA/RNA Sequencing Market, Segmentation by Technology

The Global Targeted DNA/RNA Sequencing Market has been segmented by Technology into NGS and Others.

Exome sequencing represents a powerful tool for deciphering the protein-coding regions of the genome, enabling comprehensive analysis of genetic variants associated with diseases such as cancer, inherited disorders, and complex traits. Enrichment sequencing techniques, on the other hand, focus on capturing specific genomic regions of interest, allowing researchers to target and sequence relevant portions of the genome with high precision and depth.

Amplicon sequencing methodology amplifies specific DNA fragments of interest through polymerase chain reaction (PCR), facilitating targeted analysis of genes, genomic regions, or microbial communities. This approach finds widespread utility in applications such as cancer gene sequencing, inherited disease screening, and microbial profiling through 16S ribosomal RNA (rRNA) sequencing. Additionally, NGS-based methods are increasingly employed in forensic genomics, leveraging the high-throughput and sensitivity of sequencing technologies to analyze DNA evidence and aid in criminal investigations.

These diverse methodologies within the Global NGS Targeted DNA/RNA Sequencing Market cater to a broad spectrum of applications, ranging from basic research to clinical diagnostics and beyond. As the field continues to evolve, advancements in NGS technology and methodological innovations promise to further enhance the precision, throughput, and cost-effectiveness of targeted DNA/RNA sequencing, driving continued growth and innovation in genomic research and personalized medicine.

Global Targeted DNA/RNA Sequencing Market, Segmentation by Workflow

The Global Targeted DNA/RNA Sequencing Market has been segmented by Workflow into Pre-sequencing, Sequencing and Data Analysis.

Pre-sequencing encompasses sample preparation, library construction, and target enrichment, laying the groundwork for efficient and robust sequencing. During this stage, DNA or RNA samples undergo extraction and purification, followed by fragmentation and adapter ligation to generate sequencing libraries. Target enrichment methods, such as PCR amplification or hybridization-based capture, are employed to selectively enrich specific genomic regions or transcripts of interest, enhancing sequencing depth and efficiency.

Sequencing represents the core phase of the workflow, where the prepared libraries are subjected to high-throughput sequencing platforms, such as Illumina, Ion Torrent, or Pacific Biosciences systems. These platforms employ different sequencing chemistries and technologies, including sequencing by synthesis (SBS), semiconductor sequencing, and single-molecule real-time (SMRT) sequencing, offering diverse capabilities in terms of read length, throughput, and error rates.

Following sequencing, data analysis is paramount for extracting meaningful insights from the generated sequencing data. This stage involves bioinformatics analysis, including read alignment, variant calling, gene expression quantification, and functional annotation. Advanced computational algorithms and software tools are utilized to process raw sequencing data, filter out noise, and interpret genomic variations in the context of biological pathways, disease mechanisms, and clinical relevance.

The integration of pre-sequencing, sequencing, and data analysis workflows in targeted DNA/RNA sequencing enables researchers and clinicians to unravel the complexities of the genome and transcriptome with precision and efficiency. As sequencing technologies and bioinformatics tools continue to advance, the seamless integration of these workflow stages promises to drive innovation and accelerate discoveries in genomic research, personalized medicine, and beyond.

Global Targeted DNA/RNA Sequencing Market, Segmentation by Application

The Global Targeted DNA/RNA Sequencing Market has been segmented by Application into Human Biomedical Research, Plant & Animal Sciences, Drug Discovery and Others.

One prominent application lies within human biomedical research, where targeted sequencing is instrumental in elucidating the genetic basis of diseases, identifying biomarkers, and advancing our understanding of human biology. Researchers leverage targeted sequencing to explore cancer gene sequencing, inherited disease screening, pharmacogenomics, and population genetics, among other areas, paving the way for precision medicine and personalized healthcare interventions.

In the realm of plant and animal sciences, targeted DNA/RNA sequencing plays a pivotal role in agricultural biotechnology, biodiversity studies, and evolutionary research. Scientists utilize targeted sequencing to characterize plant and animal genomes, decipher genetic traits related to crop improvement, disease resistance, and environmental adaptation, and trace the evolutionary history of species. By harnessing the power of targeted sequencing, researchers can accelerate breeding programs, enhance agricultural productivity, and conserve endangered species, contributing to global food security and biodiversity conservation efforts.

Targeted DNA/RNA sequencing holds immense promise in drug discovery and development, where it serves as a cornerstone for identifying therapeutic targets, elucidating drug mechanisms of action, and optimizing treatment strategies. Pharmaceutical companies leverage targeted sequencing to conduct pharmacogenomic studies, stratify patient populations based on genetic markers, and guide the development of precision therapeutics tailored to individual patients. Additionally, targeted sequencing enables the exploration of microbial communities and infectious disease pathogens, facilitating drug discovery efforts in antimicrobial resistance and infectious disease management.

Beyond these core applications, targeted DNA/RNA sequencing finds use in a myriad of other fields, including forensic genomics, environmental microbiology, and microbial ecology. Forensic scientists employ targeted sequencing to analyze DNA evidence and aid in criminal investigations, while environmental researchers utilize sequencing technologies to study microbial communities in diverse ecosystems and monitor environmental changes. The versatility and adaptability of targeted DNA/RNA sequencing across a wide spectrum of applications underscore its transformative potential in advancing scientific knowledge, improving healthcare outcomes, and addressing global challenges across disciplines.

Global Targeted DNA/RNA Sequencing Market, Segmentation by Type

The Global Targeted DNA/RNA Sequencing Market has been segmented by Type into DNA Based Targeted Sequencing and RNA Based Targeted Sequencing.

DNA-based targeted sequencing focuses on elucidating the genetic blueprint encoded within the DNA molecules, enabling precise analysis of genomic regions associated with diseases, traits, or biological functions of interest. This approach involves selectively enriching specific DNA sequences or genomic regions through methodologies such as exome sequencing, enrichment sequencing, or amplicon sequencing. DNA-based targeted sequencing finds applications in various fields, including cancer genetics, inherited disease screening, population genetics, and forensic genomics. By sequencing specific regions of the genome with high coverage and accuracy, researchers can uncover genetic variations, mutations, and structural rearrangements linked to diseases or phenotypic traits, informing clinical diagnostics, personalized medicine, and biomedical research endeavors.

In contrast, RNA-based targeted sequencing focuses on profiling the transcriptome—the complete set of RNA molecules expressed within a cell, tissue, or organism. This approach involves sequencing RNA transcripts derived from genes of interest, providing insights into gene expression levels, alternative splicing events, RNA modifications, and transcript isoform diversity. RNA-based targeted sequencing methodologies, such as RNA-seq and targeted RNA panels, enable researchers to investigate gene expression patterns, identify novel RNA transcripts, and elucidate regulatory mechanisms underlying physiological processes, disease states, and drug responses. Applications of RNA-based targeted sequencing span diverse fields, including cancer research, developmental biology, neurology, and infectious disease studies, offering valuable insights into gene expression dynamics and RNA-based biomarkers for diagnostic, prognostic, and therapeutic purposes.

Together, DNA-based and RNA-based targeted sequencing techniques empower researchers and clinicians to explore the intricacies of the genome and transcriptome with precision and depth, facilitating the discovery of genetic variants, gene expression signatures, and molecular pathways underlying health and disease. By leveraging the complementary strengths of these sequencing approaches, scientists can unravel the complexities of biological systems and advance our understanding of human biology, plant and animal physiology, and microbial ecology, shaping the future of genomics-driven research and personalized medicine.

Global Targeted DNA/RNA Sequencing Market, Segmentation by End Use

The Global Targeted DNA/RNA Sequencing Market has been segmented by End Use into Academic Research, Hospitals & Clinics, Pharma & Biotech Entities and Other.

Academic research institutions serve as key hubs for innovation and discovery, driving advancements in genomics, transcriptomics, and personalized medicine. Academic researchers leverage targeted sequencing to investigate fundamental biological questions, unravel disease mechanisms, and develop novel therapeutic interventions. By harnessing the power of sequencing technologies, academic researchers contribute to the collective knowledge base, propel scientific breakthroughs, and train the next generation of scientists and clinicians.

Hospitals and clinics represent crucial settings for the translation of genomic insights into clinical practice, offering diagnostic, prognostic, and therapeutic solutions tailored to individual patients. Within healthcare settings, targeted DNA/RNA sequencing plays a pivotal role in genetic testing, disease diagnosis, and treatment selection across various specialties, including oncology, pediatrics, cardiology, and rare diseases. Clinicians utilize sequencing technologies to identify disease-causing mutations, predict treatment responses, and monitor disease progression, enabling precision medicine approaches that optimize patient outcomes and improve healthcare delivery.

Pharmaceutical and biotechnology companies leverage targeted sequencing to accelerate drug discovery and development pipelines, from target identification and validation to clinical trial stratification and biomarker discovery. By integrating genomic data into drug development workflows, pharmaceutical companies enhance the efficiency of drug discovery, increase the success rate of clinical trials, and advance the development of precision therapeutics tailored to specific patient populations. Targeted sequencing also facilitates pharmacogenomic studies, enabling the identification of genetic factors influencing drug response variability and adverse drug reactions, thereby guiding personalized treatment strategies and enhancing medication safety.

Beyond these primary end-users, targeted DNA/RNA sequencing finds applications in a wide range of industries and research sectors, including agricultural biotechnology, environmental monitoring, forensic science, and veterinary diagnostics. These diverse end-users reflect the versatility and cross-disciplinary nature of sequencing technologies, which continue to drive innovation, foster collaboration, and revolutionize our understanding of biology and disease across academia, healthcare, and industry.

Global Targeted DNA/RNA Sequencing Market, Segmentation by Geography

In this report, the Global Targeted DNA/RNA Sequencing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Targeted DNA/RNA Sequencing Market Share (%), by Geographical Region, 2024

North America, particularly the United States and Canada, stands as a leading hub for genomic research, driven by robust funding support, advanced infrastructure, and a thriving biotechnology ecosystem. The region boasts a strong presence of academic research institutions, biotechnology companies, and healthcare organizations, driving innovation in targeted DNA/RNA sequencing technologies and applications across diverse fields, including oncology, neurology, and infectious diseases.

Europe represents another prominent market for targeted DNA/RNA sequencing, characterized by a rich scientific heritage, collaborative research networks, and stringent regulatory standards. Countries such as the United Kingdom, Germany, and France play pivotal roles in advancing genomic medicine, fostering interdisciplinary collaborations, and translating genomic discoveries into clinical practice. European initiatives, such as the European Genome-phenome Archive (EGA) and the European Molecular Biology Laboratory (EMBL), contribute to the region's leadership in genomic research and data sharing initiatives.

In the Asia Pacific region, countries like China, Japan, and India are witnessing rapid growth in genomic research and personalized medicine initiatives, fueled by increasing investments in healthcare infrastructure, rising prevalence of chronic diseases, and expanding biotechnology industry. Asian countries leverage targeted DNA/RNA sequencing technologies to address population-specific healthcare challenges, accelerate drug discovery efforts, and enhance agricultural productivity through genomic breeding programs.

The Middle East and Africa region, while emerging as a nascent market for genomics, shows promising growth potential driven by rising healthcare expenditures, increasing awareness of genetic diseases, and government initiatives to strengthen healthcare infrastructure. Countries like Israel, Saudi Arabia, and South Africa are at the forefront of genomic research and precision medicine initiatives, driving the adoption of targeted DNA/RNA sequencing technologies to address regional health disparities and improve patient outcomes.

Latin America represents another dynamic market for targeted DNA/RNA sequencing, marked by a growing biotechnology sector, expanding research capabilities, and increasing collaborations with international partners. Countries such as Brazil, Mexico, and Argentina are investing in genomic research infrastructure, fostering partnerships between academia, industry, and government agencies to accelerate genomic medicine and address public health challenges unique to the region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Targeted DNA/RNA Sequencing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Precision Medicine
• Personalized Healthcare
• Advancements in Sequencing Technologies

• Decreasing Sequencing Costs - The decreasing costs of DNA/RNA sequencing have been a significant catalyst for the expansion and democratization of genomic research and clinical applications worldwide. Over the past decades, advancements in sequencing technologies, coupled with improvements in workflow efficiency and economies of scale, have driven substantial reductions in sequencing costs, making genomic analysis more accessible and cost-effective than ever before. This trend has empowered researchers, clinicians, and biotechnology companies to conduct large-scale genomic studies, explore diverse applications of sequencing technologies, and translate genomic insights into actionable clinical interventions.

  The decreasing sequencing costs have led to a proliferation of large-scale genomics projects, including population-scale sequencing initiatives, cohort studies, and disease-specific research consortia. These projects leverage the affordability of sequencing technologies to interrogate the genomes of thousands to millions of individuals, enabling the discovery of novel genetic variants associated with diseases, traits, and drug responses. By harnessing the power of big data and large sample sizes, researchers can uncover complex genetic architectures underlying human health and disease, facilitating the development of precision medicine approaches tailored to individual patients' genetic profiles.

  Furthermore, the declining costs of DNA/RNA sequencing have catalyzed innovation and competition within the genomics industry, driving continuous improvements in sequencing platforms, reagent kits, and bioinformatics tools. Companies are investing in research and development efforts to enhance sequencing throughput, accuracy, and cost-efficiency, aiming to capture larger market shares and meet the growing demand for genomic analysis across diverse research and clinical settings. As sequencing costs continue to decline and technological innovations persist, the global DNA/RNA sequencing market is poised for further expansion, paving the way for transformative advancements in healthcare, agriculture, and beyond.

Restraints

• High Initial Investment Costs
• Complex Data Analysis and Interpretation
• Data Privacy and Security Concerns

• Regulatory Challenges and Compliance Requirements - Regulatory challenges and compliance requirements represent significant hurdles for the Global Targeted DNA/RNA Sequencing Market, impacting various aspects of research, development, and clinical implementation. One key challenge involves navigating the complex landscape of regulatory frameworks governing genomic data privacy, security, and ethical considerations. Different countries and regions have distinct regulations governing the collection, storage, and sharing of genomic data, posing challenges for multinational research collaborations and data sharing initiatives. Compliance with these regulations necessitates robust data management strategies, secure infrastructure, and transparent consent procedures to ensure patient privacy and confidentiality.

  Regulatory requirements for clinical validation, analytical performance, and quality assurance present challenges for the translation of targeted DNA/RNA sequencing technologies into clinical diagnostics and personalized medicine applications. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose stringent standards for the analytical validity, clinical utility, and safety of genomic tests, necessitating comprehensive validation studies, analytical validation protocols, and documentation of test performance characteristics. Meeting these regulatory requirements entails significant time, resources, and expertise, delaying market entry and commercialization of genomic diagnostics and therapeutic products.

  Additionally, reimbursement policies and coverage determinations pose regulatory challenges for targeted DNA/RNA sequencing-based tests, affecting market adoption and healthcare reimbursement strategies. Payers, including government agencies, private insurers, and healthcare systems, evaluate the clinical utility, cost-effectiveness, and evidence base of genomic tests when making reimbursement decisions, often requiring rigorous clinical evidence demonstrating improved patient outcomes and healthcare cost savings. Addressing these regulatory challenges requires collaboration between industry stakeholders, regulatory agencies, healthcare providers, and payers to develop transparent reimbursement pathways, evidence-based guidelines, and regulatory pathways that facilitate timely market access and adoption of genomic innovations.

  Regulatory challenges and compliance requirements represent complex and evolving aspects of the Global Targeted DNA/RNA Sequencing Market, influencing research, development, clinical implementation, and market access strategies. Overcoming these challenges requires multidisciplinary expertise, collaboration, and proactive engagement with regulatory agencies and stakeholders to navigate regulatory pathways, address compliance requirements, and accelerate the translation of genomic discoveries into clinical practice and public health interventions.

Opportunities

• Expansion of Precision Medicine Initiatives
• Integration of Genomic Data into Clinical Practice
• Development of Companion Diagnostics

• Adoption of Liquid Biopsies for Non-invasive Testing - The adoption of liquid biopsies for non-invasive testing represents a transformative opportunity within the Global Targeted DNA/RNA Sequencing Market, offering a paradigm shift in disease diagnosis, monitoring, and treatment. Liquid biopsies involve the analysis of circulating biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs), obtained from minimally invasive bodily fluids such as blood, urine, or cerebrospinal fluid. This approach enables clinicians to obtain real-time information about tumor dynamics, genetic mutations, and treatment responses, without the need for invasive tissue biopsies, which may be challenging or inaccessible in certain clinical scenarios.

  One of the key drivers propelling the adoption of liquid biopsies is their potential to revolutionize cancer care by providing early detection, prognostic information, and personalized treatment strategies. Liquid biopsies offer a non-invasive means to monitor tumor evolution, detect minimal residual disease, and identify actionable mutations for targeted therapy selection or monitoring of treatment response and resistance. Additionally, liquid biopsies hold promise for screening asymptomatic individuals at high risk for cancer, enabling earlier detection and intervention when treatment is most effective, thereby improving patient outcomes and reducing healthcare costs associated with late-stage cancer care.

  The adoption of liquid biopsies extends beyond oncology to other clinical applications, including prenatal testing, infectious disease diagnostics, and transplant monitoring. In prenatal testing, liquid biopsies enable non-invasive prenatal screening for chromosomal abnormalities, genetic disorders, and fetal genetic conditions, offering a safer alternative to invasive procedures such as amniocentesis or chorionic villus sampling. Similarly, in infectious disease diagnostics, liquid biopsies facilitate the detection of pathogen-derived nucleic acids, proteins, or exosomes in bodily fluids, enabling rapid and sensitive diagnosis of infectious diseases such as HIV, hepatitis, and COVID-19.

  The widespread adoption of liquid biopsies faces challenges related to assay standardization, analytical validation, and clinical utility assessment. Standardization of sample collection, processing, and analysis protocols is critical to ensure reproducibility, accuracy, and reliability of liquid biopsy assays across different laboratories and platforms. Additionally, rigorous analytical validation studies are needed to establish the sensitivity, specificity, and clinical performance characteristics of liquid biopsy tests for different clinical indications. Furthermore, evidence generation and clinical validation studies are essential to demonstrate the clinical utility, cost-effectiveness, and impact on patient outcomes of liquid biopsy-based testing strategies, addressing regulatory requirements and payer reimbursement considerations.

  The adoption of liquid biopsies for non-invasive testing presents a compelling opportunity to transform disease management across multiple clinical specialties, offering enhanced diagnostic capabilities, personalized treatment strategies, and improved patient outcomes. Overcoming challenges related to assay standardization, analytical validation, and evidence generation will be crucial to realizing the full potential of liquid biopsy-based testing in clinical practice and public health interventions.

Key players in Global Targeted DNA/RNA Sequencing Market include;

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies
• PierianDx
• Genomatix GmbH
• GATC Biotech Ag
• Oxford Nanopore Technologies
• Macrogen, Inc.
• Thermo Fisher Scientific
• QIAGEN

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis